Enhancement of chronic cyclosporine nephrotoxicity by sodium depletion in an experimental mouse model

Nephrology

Volumn 3, Issue 6, 1997, Pages 471-478

  Andoh, Takeshi F ^a   Lam, Tri T ^a   Lindsley, Jessie ^a   Alpers, Charles E ^b   Bennett, William M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Arteriolopathy; Cyclosporine; Knockout mouse; Mice; Nephrotoxicity; Renin angiotensin system tubulointerstitial fibrosis

Indexed keywords

CREATININE; CYCLOSPORIN A; NITROGEN; OLIVE OIL; PLACEBO; SODIUM; UREA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSE RESPONSE; DRUG INDUCED DISEASE; HISTOPATHOLOGY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM DEPLETION; SODIUM RESTRICTION; SUBCUTANEOUS DRUG ADMINISTRATION; UREA NITROGEN BLOOD LEVEL;

EID: 0030729463     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.1997.tb00271.x     Document Type: Article

References (24)

1. Greenberg A, Egel J, Thompson M et al. Early and late forms of cyclosporine nephrotoxicity: Studies in cardiac transplant recipients. Am. J. Kidney Dis. 1987; 9: 12-22
2. Myers B, Newton L, Boshkos C et al. The long-term course of cyclosporine-associated chronic nephropathy. Kidney Int. 1988; 33: 590-600.
3. Myers B. Cyclosporine nephrotoxicity. Kidney Int. 1986; 30: 964-74.
4. Bennett WM, DeMattos A, Meyer MM, Andoh TF, Barry JM. Chronic cyclosporine nephropathy: The achilles' heel of immunosuppressive therapy. Kidney Int. 1996; 50: 1089-100.
5. Myers B, Newton L, Boshkos C. Chronic injury of human renal microvessels with low-dose cyclosporine therapy. Transplantation. 1988; 46: 694-703.
6. English J, Evan A, Houghton DC, Bennett WM. Cyclosporine-induced acute renal dysfunction in the rat. Transplantation. 1987; 44: 135-41.
7. Elzinga L, Rosen S, Bennett WM. Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: role of sodium intake. J. Am. Soc. Nephrol. 1993; 4: 214-21.
8. Young BA, Burdmann EA, Johnson RJ et al. Cyclosporine A induced arteriolopathy in a rat model of chronic cyclosporine nephropathy. Kidney Int. 1995; 48: 431-8.
9. Young BA, Burdmann EA, Johnson RJ et al. Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. Kidney Int. 1995; 48: 439-48.
10. Rossi NF, Churchill PC, McDonald FD, Ellis VR. Mechanism of cyclosporine A-induced renal vasoconstriction in the rat. J. Pharmacol. Exp. Ther. 1989; 250: 896-901.
11. Rosen S, Greenfeld Z, Brezis M. Chronic cyclosporine-induced nephropathy in the rat. Transplantation 1990; 49: 445-52.
12. Pichler RH, Franceschini N, Young BA et al. Pathogenesis of cyclosporine nephropathy: Roles of angiotensin II and osteopontin. J. Am. Soc. Nephrol. 1995; 6: 1186-96.
13. Shehata M, Cope GH, Johnson TS, Raftery AT, El Nahas AM. Cyclosporine enhances the expression of TGF-β1 in the juxtaglomerular cells of the rat kidney. Kidney Int. 1995; 48: 1487-96.
14. Shihab FS, Andoh TF, Tanner AM et al. Role of transforming growth factor-β1 in experimental chronic cyclosporine nephropathy. Kidney Int. 1996; 49: 1141-51.
15. Smithies O, Kim HS. Targeted gene duplication and disruption for analyzing quantitative genetic traits in mice. Proc. Natl Acad. Sci. 1994; 91: 3612-15.
16. Tanimoto K, Sugiyama F, Goto Y et al. Angiotensinogen-deficient mice with hypotension. J. Biol. Chem. 1994; 269: 31334-7.
17. Burdmann EA, Andoh TF, Nast CC et al. Prevention of experimental cyclosporin-induced interstitial fibrosis by losartan and enalapril. Am. J. Physiol. 1995; 269: F491-9.
18. Masri MA. Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in balb/c mice with fitted skin grafts. Transplant Proc. 1995; 27: 366.
19. Wolf G, Neilson EG. Increases in levels of collagen types I and IV messenger ribonucleic acid in murine kidneys after treatment with cyclosporine. Nephron. 1992; 60: 87-91.
20. Andoh TF, Burdmann EA, Lindsley J et al. Functional and structural characteristics of experimental Fk 506 nephrotoxicity. Clin. Exp. Pharmacol. Physiol. 1995; 22: 646-54.
21. Andoh TF, Burdmann EA, Franceschini N et al. Comparison of acute rapamycin nephroxicity with cyclosporine and Fk 506. Kidney Int. 1996; 50: 1110-17.
22. Burdmann EA, Young BA, Andoh TF et al. Mechanisms of cyclosporine-induced interstitial fibrosis. Transplant. Proc. 1994; 26: 2588-9.
23. Burdmann EA, Andoh TF, Rosen S et al. Experimental nephrotoxicity, hepatotoxicity and pharmacokinetics of cyclosporin G versus cyclosporin A. Kidney Int. 1994; 45: 684-91.
24. Brezis M, Greenfeld Z, Shina A et al. Angiotensin II augments medullary hypoxia and predisposes to acute renal failure. Eur. J. Clin. Invest. 1990; 20: 199-207.